OFX-514: First-in-class peptide-based oral therapeutic
Oxalo Therapeutics has demonstrated the powerful therapeutic potential of Of-derived factors through in vivo mice studies that significantly lowered urine oxalate levels. The critical peptides from the factors were isolated to fully mimic the effects of the factors in stimulating colonic oxalate transport. We are targeting a safe daily peptide-based oral pill that stimulates and amplifies the natural intestinal oxalate-regulation pathway to remove oxalate from the plasma and urine in order to treat primary hyperoxaluria, secondary hyperoxaluria, and hyperoxalemia.
Contact us to learn more about the science and our stage of development
